Navigation Links
PI presents safety results in Neuralstem ALS Stem Cell Trial
Date:4/12/2011

s. All adverse events were resolved. In the group of ambulatory patients, all three remain ambulatory and experienced no serious adverse events secondary to surgery.

"It has been 15-to-4 months since the first nine patients have received the cells," said Karl Johe, Ph.D., Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "There have been no adverse reactions possibly or probably or definitely related to the cells. This indicates that the trial is proceeding as smoothly as can be hoped for. It is designed for transplantation to progress up to the cervical region of spinal cord as safety is demonstrated in the lumbar region," Dr. Johe continued. "With SMB and FDA review of the safety data from the 12 patients due to be completed in the next month, we hope to begin transplanting ALS patients in the cervical region this summer."

"This is significant and, we believe, compelling safety data," said Richard Garr president and CEO of Neuralstem. "It represents the first safety results from the world's first ALS neural stem cell trial, as well as the first data from Neuralstem's ongoing clinical programs. We believe it also validates our proprietary Spinal Injection Platform for the safe intraspinal delivery of our cells. We remain deeply indebted to the patients and their families who are participating in the study."

About the Study

Safety results were presented on nine patients in an ongoing Phase I study to evaluate the safety of Neuralstem's spinal cord stem cells (HSSC's), as well as the transplantation technique, in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Of these nine patients, the first six (Cohort A) were all non-ambulatory with permanent paralysis. The first of these was treated on January 20, 2010. Successive surgeries have followed at the rate of one every one-to-two months. The first three patients (Cohort A1) were treated with five unilater
'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Alfred B. Knight, M.D., Scott & White Healthcare, presents at 8th Annual World Health Care Congress
2. Cancer surgery society presents top honor to Kimberly Duchossois
3. Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
4. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
5. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
6. AAPS presents awards to exemplary researchers
7. Governor presents UH researcher with grant for cardiac device
8. Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting
9. APA presents latest research on same-sex marriage at annual convention in San Diego
10. AOSSM presents prestigious research awards at annual meeting
11. Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 A new study published ... increase in disability associated with speech problems from 2001-02 ... than 15% increase in disability associated with hearing problems. ... rising numbers of children who are experiencing communication disorders, ... , On a broader level, the new study, ...
(Date:8/21/2014)... care physicians in rural communities do not routinely ... to Penn State medical and public health researchers. ... have limited resources if they seek help., "Rural ... women," said Jennifer S. McCall-Hosenfeld, a primary care ... health sciences, Penn State College of Medicine. "However, ...
(Date:8/21/2014)... August 21, 2014 Xarelto lawsuit ( ... patients to suffer uncontrollable internal bleeding and other serious ... LLP reports. According to court documents, a wrongful death ... Court, Easter District of New York by the family ... bleeding event that was allegedly caused by Xarelto. Among ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... manufactured by Boston Scientific has begun in Massachusetts ... bellwether trial. The Rottenstein Law Group LLP, a ... with claims of harm stemming from the implantation ... claim for compensation for injuries suffered at ...
(Date:8/21/2014)... Annapolis, MD (PRWEB) August 21, 2014 ... real estate organizations to obtain industry-focused data, is ... out healthcare real estate data on the Southeast, ... RevistaMed.com/PropertySearch – the first widely available, ... , The total number of searchable properties, including ...
Breaking Medicine News(10 mins):Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5
... , TUESDAY, Feb. 1 (HealthDay News) -- Many black ... interaction stressful and don,t feel physicians give them enough useful ... suggests. The findings stem from a series of focus ... result: doctors are viewed as coming up short when it ...
... cancer cells dodge the immune system and promote tumor growth, ... disease. While comparable mechanisms to avoid the immune system have ... study tested human breast tumor cells, putting researchers closer to ... The study, published in the journal Cancer Research , ...
... targeted breast biopsies for patients with early breast cancer, ... from undergoing a second breast cancer surgery, a new ... undergo a sentinel lymph node biopsy to determine if ... author of the study. Ultrasound, on its own, ...
... , TUESDAY, Feb. 1 (HealthDay News) -- Finally some good ... with their parents behave better, have stronger mental health and ... study. Researchers at Brigham Young University,s School of Family ... to 16. They found that the most popular video games ...
... screening for breast cancer delivers consistent rates of cancer detection ... study published online and in the April print edition of ... than mammography at identifying suspicious areas of the breast, it ... lesions, which can result in additional testing and false-positive results ...
... published a new international multidisciplinary classification of lung adenocarcinoma, ... The new classification is published in the February ... the official publication of the International Association for the ... rapid advances in lung adenocarcinoma affecting clinical, radiologic, pathologic, ...
Cached Medicine News:Health News:Study Examines Reasons Some Black Men Avoid Doctors 2Health News:Breast cancer cells outsmart the immune system and thrive 2Health News:Breast cancer cells outsmart the immune system and thrive 3Health News:Microbubble ultrasound and breast biopsies 2Health News:Girls Win When They Play Video Games With Parents: Study 2Health News:Repeat MRI screening for breast cancer results in fewer false positives 2Health News:Lung societies unveil new international classification of lung adenocarcinoma 2
(Date:8/21/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced positive results from a randomized, double-blind Phase ... for the treatment of edematous fibrosclerotic panniculopathy (EFP), ... trial, all three doses of CCH (low (0.06mg), ... in the appearance of cellulite as measured by ...
(Date:8/20/2014)... Aug. 20, 2014 The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kansas blocked the sale of more ...
(Date:8/20/2014)... NEW YORK , Aug. 20, ... a new market research report is ... The Market for Hospital-Acquired Infection Control ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... and healthcare-associated infections (HAIs), demand has ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... 2007 /PRNewswire-FirstCall/ --,Pharmacyclics, Inc. announced today multiple ... gadolinium),Injection, including an oral presentation of Phase ... Gadolinium And Radiation,Therapy) trial data. The presentations ... the 2007 American Society of Clinical Oncology,Annual ...
... Potential Benefit of Unique OROS(R),Formulation, SAN DIEGO, ... abuse,remains an ongoing concern for parents and ... Hyperactivity Disorder,(ADHD). Data presented on Tuesday at ... Association highlighted findings that,long-acting OROS(R) methylphenidate had ...
Cached Medicine Technology:Pharmacyclics Announces Presentations and Published Abstracts on,Xcytrin at The 2007 American Society of Clinical Oncology Annual,Meeting 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 3New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 4New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: